Subcutaneous exendin treats post-bariatric hypoglycemia

August 11, 2017

(HealthDay)—Subcutaneous exendin (SC Ex-9) appears to be safe and effective in treating post-bariatric hypoglycemia (PBH), according to a study published online Aug. 4 in Diabetes, Obesity and Metabolism.

Colleen M. Craig, M.D., from the Stanford University School of Medicine in California, and colleagues conducted the first in-human subcutaneous administration of Ex-9 in nine female patients with PBH following Roux-en-Y gastric bypass. First, a single participant underwent equimolar low-dose IV versus subcutaneous Ex-9 administration. Then, eight participants were administered single ascending doses of SC Ex-9 during testing.

The researchers observed an exposure-response relationship, but all doses effectively prevented hyperinsulinemic hypoglycemia and improved associated symptoms. The postprandial glucose nadir was increased by 66 percent, peak insulin was reduced by 57 percent, and neuroglycopenic symptoms were reduced by 80 percent, on average. No treatment-related adverse events were reported.

"SC Ex-9 appears to represent a safe, effective, and targeted therapeutic approach for treatment of PBH," the authors write. "Further investigation involving multiple doses with chronic dosing is warranted."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Similar defects ID'd for T2DM, chronic pancreatitis and diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Similar defects ID'd for T2DM, chronic pancreatitis and diabetes

August 2, 2017
(HealthDay)—Patients with type 2 diabetes and those with diabetes secondary to chronic pancreatitis have similarly impaired α-cell responses to oral glucose ingestion and hypoglycemia, according to a study published online ...

G-pen may aid hypoglycemia with type 1 diabetes

February 22, 2016
(HealthDay)—Mini-dose glucagon administered using a stable, ready-to-use G-Pen Mini glucagon may be an effective option for mild to moderate hypoglycemia in adults with type 1 diabetes, according to a study published online ...

mAb glucagon receptor blocker suitable for further development

August 4, 2017
(HealthDay)—The glucagon receptor blocker REGN1193, a fully human monoclonal antibody, seems safe and tolerable enough for further development, according to a study published online July 28 in Diabetes, Obesity and Metabolism.

Novel oral glucose lowering drugs cut risks in T2DM

February 8, 2017
(HealthDay)—For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, ...

Gastric bypass cuts hormonal responses to hypoglycemia

June 29, 2016
(HealthDay)—Gastric bypass (GBP) surgery is associated with reduced symptoms and neurohormonal responses to hypoglycemia, according to a study published online June 16 in Diabetes.

Blunted, more variable insulin action in lipohypertrophy

July 28, 2016
(HealthDay)—Insulin lispro injection into lipohypertrophic tissue (LHT) results in considerable impairment and increased variability in insulin absorption and action, according to a study published in online July 13 in ...

Recommended for you

Finding a natural defense against clogged arteries

September 20, 2017
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective ...

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

September 14, 2017
A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes ...

Epigenetic 'fingerprint' identifies diabetes risk

September 14, 2017
Deakin researchers have identified an epigenetic marker that predicts risk of type 2 diabetes in women with gestational diabetes.

Could swine flu be linked to type 1 diabetes?

September 14, 2017
(HealthDay)—Young people who've been infected with the H1N1 swine flu virus may be at increased risk for type 1 diabetes, a new study suggests.

Time to dial back on diabetes treatment in older patients? Study finds 11 percent are overtreated

September 14, 2017
Anyone with diabetes who takes blood sugar medication knows their doctor prescribed it to help them. After all, the long-term effects of elevated blood sugar can harm everything from the heart and kidneys to the eyes and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.